{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=18", "query": { "intervention": "Chemotherapeutic Agent", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 599, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T04:50:33.414Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06877533", "title": "A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Selected Advanced Solid Tumors" ], "interventions": [ { "name": "EOS006215", "type": "DRUG" }, { "name": "Anticancer agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "iTeos Belgium SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2025-04-07", "completion_date": "2025-07-10", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-10-15T04:50:33.414Z", "location_count": 2, "location_summary": "Denver, Colorado • Sarasota, Florida", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06877533" }, { "nct_id": "NCT00002137", "title": "A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma, Kaposi", "HIV Infections" ], "interventions": [ { "name": "Tecogalan sodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-15T04:50:33.414Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002137" }, { "nct_id": "NCT06564038", "title": "A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukaemia", "Small Lymphocytic Lymphoma", "Mantle-cell Lymphoma", "Large B-cell Lymphoma", "B-cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Surovatamig", "type": "DRUG" }, { "name": "Prednisone (or equivalent)", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 408, "start_date": "2025-01-30", "completion_date": "2029-06-11", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-15T04:50:33.414Z", "location_count": 12, "location_summary": "Boston, Massachusetts • Hackensack, New Jersey • New Brunswick, New Jersey + 8 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06564038" }, { "nct_id": "NCT07397338", "title": "Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Solid Tumors", "Non-small Cell Lung Cancer (NSCLC)", "NSCLC", "Colorectal Cancer (CRC)", "CRC" ], "interventions": [ { "name": "Daraxonrasib", "type": "DRUG" }, { "name": "Elironrasib", "type": "DRUG" }, { "name": "Zoldonrasib", "type": "DRUG" }, { "name": "Ivonescimab", "type": "DRUG" }, { "name": "Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)", "type": "DRUG" }, { "name": "cetuximab (Cohort C2 Only)", "type": "DRUG" }, { "name": "Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)", "type": "DRUG" }, { "name": "Daraxonrasib (Cohort B1 only)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 370, "start_date": "2026-01-30", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-10-15T04:50:33.414Z", "location_count": 8, "location_summary": "Los Angeles, California • Norwich, Connecticut • Saint Paul, Minnesota + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Saint Paul", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07397338" }, { "nct_id": "NCT07227298", "title": "Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced/Metastatic Non-Small Cell Lung Cancer", "Carcinoma, Non-Small Cell Lung", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "PF-08634404", "type": "BIOLOGICAL" }, { "name": "Sigvotatug Vedotin", "type": "BIOLOGICAL" }, { "name": "PF-08046054/SGN-PDL1V", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2026-01-30", "completion_date": "2033-08-23", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-15T04:50:33.414Z", "location_count": 55, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 29 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227298" }, { "nct_id": "NCT06428409", "title": "A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancer" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Leucovorin (LV) or levoleucovorin", "type": "DRUG" }, { "name": "Rescue medication", "type": "DRUG" }, { "name": "Supportive care measures", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2024-06-20", "completion_date": "2029-10-16", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-15T04:50:33.414Z", "location_count": 13, "location_summary": "Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06428409" }, { "nct_id": "NCT06589804", "title": "Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hypopharyngeal Squamous Cell Carcinoma", "Metastatic Laryngeal Squamous Cell Carcinoma", "Metastatic Oral Cavity Squamous Cell Carcinoma", "Metastatic Oropharyngeal Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Neck Squamous Cell Carcinoma of Unknown Primary", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Refractory Head and Neck Squamous Cell Carcinoma", "Refractory Hypopharyngeal Squamous Cell Carcinoma", "Refractory Laryngeal Squamous Cell Carcinoma", "Refractory Oral Cavity Squamous Cell Carcinoma", "Refractory Oropharyngeal Squamous Cell Carcinoma", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Lip and Oral Cavity Cancer AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2025-03-27", "completion_date": "2029-11-30", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-15T04:50:33.414Z", "location_count": 200, "location_summary": "Little Rock, Arkansas • Marysville, California • Palo Alto, California + 161 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Marysville", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06589804" }, { "nct_id": "NCT05231746", "title": "A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "hSTC810", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "STCube, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2022-04-18", "completion_date": "2024-02-29", "has_results": false, "last_update_posted_date": "2024-03-13", "last_synced_at": "2026-10-15T04:50:33.414Z", "location_count": 3, "location_summary": "New Haven, Connecticut • New York, New York • Houston, Texas", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05231746" }, { "nct_id": "NCT06026254", "title": "A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "IMSA101", "type": "DRUG" }, { "name": "Immune Checkpoint Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmuneSensor Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2023-09-15", "completion_date": "2025-09", "has_results": false, "last_update_posted_date": "2024-11-18", "last_synced_at": "2026-10-15T04:50:33.414Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • La Jolla, California", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06026254" }, { "nct_id": "NCT05775159", "title": "Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Biliary Tract Cancer" ], "interventions": [ { "name": "Volrustomig", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 294, "start_date": "2023-04-24", "completion_date": "2027-10-28", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-15T04:50:33.414Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05775159" } ] }